Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase II Study of ILKN421H in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07452224 is registered in ClinicalTrials.gov with iLeukon Therapeutics, Inc. as lead sponsor.

NCT NCT07452224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07452224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase II Study of ILKN421H in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
iLeukon Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 29, 2026
Completion date
October 31, 2029
Enrollment
80 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic non-small cell lung cancer (nsclc)